PDF herunterladen
CC BY-NC-ND 4.0 · Sleep Sci 2018; 11(02): 65-68
DOI: 10.5935/1984-0063.20180014
SHORT COMMUNICATION

TRODAT SPECT in patients with idiopathic REM sleep behaviour disorder

Geraldo Nunes Vieira Rizzo
1   Hospital Moinhos de Vento, Sonolab - Porto Alegre - RS - Brasil.
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Objective

to determine the value of dopamine transporter (DAT) neuroimaging radiotracer in a group of idiopathic rapid eye movement sleep behavior disorder (iRBD) patients regarding the development of a synucleinopathy. Methods: 6 retrospectively selected patients with clinical and polysomnographic diagnosis of iRBD, on treatment or not, were submitted to a single-photon emission computerized tomography (SPECT) with TRODAT. Results: Five from six patients have an abnormal test showing reduction in DAT density measured by the linkage potential on SPECT. Conclusions: TRODAT crosses the blood brain barrier, has a high affinity for DAT and is capture by SPECT. The decreased uptake of DAT tracers means a reduction in dopaminergic activity which suggest the possibility of Parkinson Disease. We have tried to reinforce iRBD as a marker of neurodegenerative disease and suggest SPECT with TRODAT as an easy method in our country to follow longitudinally these patients.

Single Photon Emission Computed Tomography Computed Tomography - REM Sleep Behavior Disorder - Parkinson Disease


Publikationsverlauf

Eingereicht: 14. November 2017

Angenommen: 07. März 2018

Artikel online veröffentlicht:
13. Oktober 2023

© 2023. Brazilian Sleep Association. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • REFERENCES

  • 1 Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, et al. MDS research criteria for prodromal Parkinson’s disease. Mov Disord. 2015;30(12):1600-11.
  • 2 Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson’s disease. Curr Opin Neurol. 2014;27(4):434-41.
  • 3 Postuma RB, Gagnon JF, Bertrand JA, Génier Marchand D, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology. 2015;84(11):1104-13.
  • 4 Iranzo A, Santamaria J, Tolosa E. Idiopathic rapid eye movement sleep behaviour disorder: diagnosis, management, and the need for neuroprotective interventions. Lancet Neurol. 2016;15(4):405-19.
  • 5 Schenck CH, Boeve BF, Mahowald MW. Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series. Sleep Med. 2013;14(8):744-8.
  • 6 Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, et al. Neurodegenerative disease status and post-morten pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol. 2013;12(5):443-53.
  • 7 Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30(12):1591-601. Figure 2. Normal exam.
  • 8 Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, et al.; Parkinson Study Group PRECEPT Investigators. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology. 2014;82(20):1791-7.
  • 9 Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson’s disease severity and duration with 123IFP- CIT SPECT striatal uptake. Mov Disord. 2000;15(4):692-8.
  • 10 Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain. 1991;114(Pt 5):2283-301.
  • 11 De la Fuente-Fernández R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL, et al. Age-specific progression of nigrostriatal dysfunction of Parkinson’s disease. Ann Neurol. 2011;69(5):803-10.
  • 12 Felicio AC, Godeiro-Junior C, Shih MC, Borges V, Silva SM, Aguiar P de C, et al. Evaluation of patients with Clinically Unclear Parkinsonian Syndromes submitted to brain SPECT imaging using the technetium-99m labeled tracer TRODAT-1. J Neurol Sci. 2010;291(1-2):64-8.
  • 13 Li Y, Kang W, Yang Q, Zhang L, Zhang L, Dong F, et al. Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases. Neurology. 2017;88(16):1493-500.